Sana Biotechnology, Inc.

As of October 31, 2025, Sana Biotechnology, Inc. has a mildly bullish technical trend, supported by mixed indicators, with a year-to-date return of 180.37% compared to the S&P 500's 16.30%, but a 3-year return of -8.6%, underperforming the S&P 500's 76.66%.

As of October 31, 2025, Sana Biotechnology, Inc. shows a mildly bullish trend, supported by bullish moving averages and Bollinger Bands, despite mixed signals from KST and OBV, with a recent performance of 33.78% over the past month compared to the S&P 500's 1.92%.

As of October 31, 2025, Sana Biotechnology, Inc. shows a mildly bullish trend with mixed signals from various indicators, having significantly outperformed the S&P 500 year-to-date with a return of 203.68%.

As of August 1, 2025, Sana Biotechnology, Inc. has a mildly bullish technical trend, supported by daily moving averages, but caution is advised due to mixed signals from MACD and KST indicators, despite strong year-to-date performance of 101.84% compared to the S&P 500's 12.22%.

As of June 18, 2025, Sana Biotechnology, Inc. is in a sideways trend with mixed technical signals, as weekly indicators show mild bullishness while monthly indicators remain bearish, indicating market indecision.

Sana Biotechnology, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $49 million and a market cap of $633.81 million. The company has no dividend yield and negative return on equity.

As of Jun 18, Sana Biotechnology, Inc. has a market capitalization of 633.81 million and reported net sales of 0.00 million with a net profit of -208.67 million over the latest four quarters. Shareholder's funds are 250.50 million, and total assets amount to 501.02 million.